Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 25, 2007
JNCI Journal of the National Cancer Institute 2007 99(19):1432-1434; doi:10.1093/jnci/djm180
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/19/1432    most recent
djm180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nelson, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Pancreatic Cancer Research Matures

Nancy J. Nelson

The first 150 words of the full text of this article appear below.

Pancreatic cancer research is a field fraught with opportunity. Early detection and effective treatments are the two biggest needs in a research area that has been slow to advance. But a closer look reveals that progress is being made on several fronts.

Researchers can now describe the progression of genetic lesions from precancer to full-blown disease. They have found candidate genes for diagnosis, screening, and treatment, many of which are being tested in trials. Several new risk factors have been identified. And a whole-genome scan of about 2,000 pancreatic cancer patients revealed new genetic targets and pathways affected by the disease.

Currently, most pancreatic cancer patients die within a year of diagnosis. By the time symptoms appear, 80% have already metastasized. The overall 5-year survival rate is about 5%, the lowest of all major cancers. Patients with localized disease who have their pancreas removed do a little better; their 5-year . . . [Full Text of this Article]

Molecular Alterations

Drug Development

Screening Efforts

Risk Factors

Future Directions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Larbouret, B. Robert, C. Bascoul-Mollevi, F. Penault-Llorca, A. Ho-Pun-Cheung, S. Morisseau, I. Navarro-Teulon, J.-P. Mach, A. Pelegrin, and D. Azria
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
Ann. Onc., November 4, 2009; (2009) mdp496v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. D. Arnold, A. V. Patel, Y. Yan, E. J. Jacobs, M. J. Thun, E. E. Calle, and G. A. Colditz
Are Racial Disparities in Pancreatic Cancer Explained by Smoking and Overweight/Obesity?
Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2397 - 2405.
[Abstract] [Full Text] [PDF]